We seek to engage in ongoing dialogue with a broad range of industry and corporate experts to develop unique and differentiated sources of information. We look to identify investment alternatives that may be mispriced or misunderstood by the broader investing community.
Our strategies also specialize in creating detailed alternative scenario analysis that can highlight potential investment opportunities. Our evolving focus is on presenting those investment cases to institutional investors in a clear and concise fashion.
Supervisory Analyst - Equity Research
Jules Augus is the Supervisory Analyst in the Equity Research department of Aegis Capital Corp. His function is to approve research reports which provide information to the public in making investment decisions. The Supervisory analyst must verify that all communications with customers and the general public are in compliance with company guidelines and security industry standards and that information presented in company reports is accurate and complete. The Supervisory analyst engages with lead research analysts and their team to improve the quality of published research. Mr. Augus has a long and varied career on Wall Street as both a generalist analyst and Research Director. He was Research Director at Stuart Coleman from 1991-1999; at Investec Ernst from 1999-2002 and at Westrock Advisors from 2008-2010. He is a graduate of the Wharton School-University of Pennsylvania with a BS in Economics.
Head of Healthcare Equity Research
Mr. Weinstein is Head of Healthcare Equity Research at Aegis Capital Corp. Mr. Weinstein has over a decade of experience in equities. Mr. Weinstein was formerly Vice President, Institutional Equities and Head of Alpha Capture at CL King & Associates and an Institutional Equities Salesperson at Sidoti & Company. At those firms, Mr. Weinstein facilitated equity research distribution, proprietary long/short idea flow, and corporate access for mutual, pension, and hedge fund clients. Mr. Weinstein began his career as a research intern at NGN Capital, a life sciences venture capital fund. Mr. Weinstein graduated from Binghamton University with a BA in Economics and English, and from New York University’s Stern School of Business with an MBA (finance concentration). Additionally, Mr. Weinstein holds the CFA designation, and the Series 7, 63, 86, and 87 licenses.
Head of Consumer Products and Special Situations | Managing Director, Supervisory Analyst
Mr. Dionisio brings over 24 year of experience as a sell-side equity analyst, having previously worked at Merrill Lynch, FBR, and Wedbush Morgan. During 2019 Mr. Dionisio was ranked #3 in the nation in his field by the Refinitiv StarMine Analyst Awards1. In the past Mr. Dionisio has won accolades from the Thomson Reuters StarMine Analyst Ranking, Wall Street Journal’s Best of the Street annual survey, and the Forbes’ Best Brokerage Analysts ranking. He frequently appears on CNBC, Bloomberg TV, and Fox Business, and has been quoted by numerous financial publications. Mr. Dionisio received his BA and MBA degrees from Duke University, where he was the P. Huber Hanes, Jr. Scholar of his class.
Financial Institutions and Cannabis Equity
Brian Hollenden, CFA has extensive experience in equity research analysis covering a wide variety of sectors including Financial Institutions, REITs, Special Situations, Lodging & Leisure and Energy. Prior to joining Aegis, Mr. Hollenden has worked in sell-side equity research at RBC Capital Markets, Truist Securities and Sidoti & Company. Prior to his sell-side experience, Brian worked on the buy-side as an Analyst at Starboard Value and as a Vice President at Ramius Capital. Mr. Hollenden started his career as an Accountant at State Street and Van Eck Global. Brian received his BSBA in Finance and Economics from Shippensburg University of Pennsylvania. He has also attended the Columbia Business School Value Investing Executive Education Program. Mr. Hollenden is a member of the CFA Society of Chicago and is a CFA charterholder.